生殖医学杂志

参考文献

[1] Shan D,Qiu PY,Wu YX,et al.Pregnancy outcomes in women of advanced maternal age:a retrospective cohort study from China[J].Sci Rep,2018,8:12239.

[2] Pastore LM,Christianson MS,Stelling J,et al.Reproductive ovarian testing and the alphabet soup of diagnoses:DOR,POI,POF,POR,and FOR[J].J Assist Reprodu Genet,2018,35:17-23.

[3] Practice Committee of the American Society for Reproductive Medicine.Testing and interpreting measures of ovarian reserve:a committee opinion[J].Fertil Steril,2015,103:e9-e17.

[4] Dogan S,Cicek OSY,Demir M,et al.The effect of growth hormone adjuvant therapy on assisted reproductive technologies outcomes in patients with diminished ovarian reserve or poor ovarian response[J].J Gynecol Obstet Hum Reprod,2021,50:101982.

[5] Cohen J,Chabbert-Buffet N,Darai E.Diminished ovarian reserve,premature ovarian failure,poor ovarian responder-a plea for universal definitions[J].J Assist Reprod Genet,2015,32:1709-1712.

[6] Jiao Z,Bukulmez O.Potential roles of experimental reproductive technologies in infertile women with diminished ovarian reserve[J].J Assist Reprod Genet,2021,38:2507-2517.

[7] 中华医学会生殖医学分会.中国高龄不孕女性辅助生殖临床实践指南[J].中国循证医学杂志，2019,19:253-270.

[8] Yu R,Jin H,Huang X,et al.Comparison of modified agonist,mild-stimulation and antagonist protocols forin vitrofertilization in patients with diminished ovarian reserve[J].J int Med Res,2018,46:2327-2337.

[9] European Society for Human Reproduction and Embryology (ESHRE)Guideline Group on POI.ESHRE Guideline:management of women with premature ovarian insufficiency[J].Hum Reprod,2016,31:926-937.

[10] 陈子江，田秦杰，乔杰，等.早发性卵巢功能不全的临床诊疗中国专家共识[J].中华妇产科杂志，2017,52:577-681.

[11] Welt CK.Primary ovarian insufficiency:a more accurate term for premature ovarian failure[J].Clin Endocrinol,2008,68:499-509.

[12] 武学清，孔蕊，田莉，等.卵巢低反应专家共识[J].生殖与避孕，2015,35:71-79.

[13] Ferraretti AP,La Marca A,Fauser BC,et al.ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization:the Bologna criteria[J].Hum Reprod,2011,26:1616-1624.

[14] Humaidan P,Alviggi C,Fischer R,et al.The novel POSEIDON stratification of ‘Low prognosis patients in Assisted Reproductive Technology’ and its proposed marker of successful outcome[J].F1000Res,2016,5:2911.

[15] Haahr T,Dosouto C,Alviggi C,et al.Management strategies for POSEIDON Groups 3 and 4[J].Front Endocrinol (Lausanne),2019,10:614.

[16] Sun W,Stegmann BJ,Henne M,et al.A new approach to ovarian reserve testing[J].Fertil Steril,2008,90:2196-2202.

[17] Jiao X,Zhang X,Li N,et al.Treg deficiency-mediated TH1 response causes human premature ovarian insufficiency through apoptosis and steroidogenesis dysfunction of granulosa cells[J].Clin Transl Med,2021,11:e448.

[18] 中华医学会妇产科学分会绝经学组.中国绝经管理与绝经激素治疗指南(2018)[J].协和医学杂志，2018,9:512-525.

[19] 中华预防医学会妇女保健分会更年期保健学组.更年期妇女保健指南(2015年)[J].实用妇科内分泌杂志(电子版),2016,3:21-32.

[20] 中国医师协会全科医师分会，北京妇产学会社区与基层分会.更年期妇女健康管理专家共识(基层版)[J].中国全科医学，2021,24:1317-1323.

[21] Tal R,Seifer DB.Ovarian reserve testing:a user’s guide[J].Am J Obstet Gynecol,2017,217:129-140.

[22] Broer SL,Broekmans FJ,Laven JS,et al.Anti-Mullerian hormone:ovarian reserve testing and its potential clinical implications[J].Hum Reprod Update,2014,20:688-701.

[23] Zhang HH,Xu PY,Wu J,et al.Dehydroepiandrosterone improves follicular fluid bone morphogenetic protein-15 and accumulated embryo score of infertility patients with diminished ovarian reserve undergoing in vitro fertilization:a randomized controlled trial[J].J ovarian Res,2014,7:93.

[24] Smotrich DB,Widra EA,Gindoff PR,et al.Prognostic value of day 3 estradiol on in vitro fertilization outcome[J].Fertil Steril,1995,64:1136-1140.

[25] Committee opinion no.618:Ovarian reserve testing[J].Obstet Gynecol,2015,125:268-273.

[26] American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee.Female age-related fertility decline.Committee Opinion No.589[J].Fertil Steril,2014,101:633-634.

[27] Gaskins AJ,Rich-Edwards JW,Missmer SA,et al.Association of fecundity with changes in adult female weight[J].Obstet Gynecol,2015,126:850-858.

[28] Practice Committee of the American Society for Reproductive Medicine.Comparison of pregnancy rates for poor responders using IVF with mild ovarian stimulation versus conventional IVF:a guideline[J].Fertil Steril,2018,109:993-999.

[29] Bukulmez O.The International Society for Mild Approaches in Assisted Reproduction (ISMAAR)definitions for mild stimulation and their rationale for assisted reproductive technologies[A].in:in:Bukulmez O(ed).Diminished ovarian reserve and assisted reproductive technologies[M].Springer,2020:141-149.

[30] Shang W.Traditional Chinese Medicine for assisted reproductive technology[A].in:Bukulmez O(ed).Diminished ovarian reserve and assisted reproductive technologies[M].Springer,2020:75-104.

[31] Nargund G,Fauser B,Macklon N,et al.The ISMAAR proposal on terminology for ovarian stimulation for IVF[J].Hum Reprod,2007,22:2801-2804.

[32] Youssef M,Van Wely M,Al-Inany H,et al.A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF:a multicenter randomized non-inferiority trial[J].Hum Reprod,2017,32:112-118.

[33] Klinkert E,Broekmans F,Looman C,et al.Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment:a randomized controlled trial[J].Hum Reprod,2005,20:611-615.

[34] 黄存，孟艳，钱易，等.低剂量Gn联合克罗米芬刺激方案在IVF/ICSI中的应用[J].生殖医学杂志，2017,26:961-966.

[35] 张潇潇，吕群.探讨高龄体外受精患者温和刺激方案中生长激素预处理的疗效[J].检验医学与临床，2018,15:900-902.

[36] Chu K,Pang W,Sun N,et al.Outcomes of poor responders following growth hormone co-treatment with IVF/ICSI mild stimulation protocol:a retrospective cohort study[J].Arch Gynecol Obstet,2018,297:1317-1321.

[37] Drakopoulos P,Bardhi E,Boudry L,et al.Update on the management of poor ovarian response in IVF:the shift from Bologna criteria to the POSEIDON concept[J].Ther Adv Reprod Health,2020,14:2633494120941480.

[38] Sunkara SK,Coomarasamy A,Faris R,et al.Long gonadotropin-releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization:a randomized controlled trial[J].Fertil Steril,2014,101:147-153.

[39] Prapas Y,Petousis S,Dagklis T,et al.GnRH antagonist versus long GnRH agonist protocol in poor IVF responders:a randomized clinical trial[J].Eur J Obstet Gynecol Reprod Biol,2013,166:43-46.

[40] Pu D,Wu J,Liu J.Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF[J].Hum Reprod,2011,26:2742-2749.

[41] Berkkanoglu M,Ozgur K.What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders?[J].Fertil Steril,2010,94:662-665.

[42] Baker VL,Brown MB,Luke B,et al.Gonadotropin dose is negatively correlated with live birth rate:analysis of more than 650,000 assisted reproductive technology cycles[J].Fertil Steril,2015,104:1145-1152.

[43] Alviggi C,Conforti A,Esteves SC,et al.Recombinant luteinizing hormone supplementation in assisted reproductive technology:a systematic review[J].Fertil Steril,2018,109:644-664.

[44] Vaiarelli A,Cimadomo D,Trabucco E,et al.Double stimulation in the same ovarian cycle (DuoStim)to maximize the number of oocytes retrieved from poor prognosis patients:a multicenter experience and SWOT analysis[J].Front Endocrinol (Lausanne),2018,9:317.

[45] Lainas TG,Sfontouris IA,Venetis CA,et al.Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders[J].Hum Reprod,2015,30:2321-2330.

[46] Polyzos N,Blockeel C,Verpoest W,et al.Live birth rates following natural cycle IVF in women with poor ovarian response according to the Bologna criteria[J].Hum Reprod,2012,27:3481-3486.

[47] Xu YM,Hao GM,Gao BL.Application of growth hormone in in vitro fertilization[J].Front Endocrinol (Lausanne),2019,10:502.

[48] 李月，康晓敏，武泽.生长激素在体外受精助孕中的应用进展[J].中华生殖与避孕杂志，2020,40:129-133.

[49] Tesarik J,Hazout A,Mendoza C.Improvement of delivery and live birth rates after ICSI in women aged >40 years by ovarian co-stimulation with growth hormone[J].Hum Reprod,2005,20:2536-2541.

[50] Weall B,Al-Samerria S,Conceicao J,et al.A direct action for GH in improvement of oocyte quality in poor-responder patients[J].Reproduction,2015,149:147-154.

[51] Hou HY,Wang X,Yu Q,et al.Evidence that growth hormone can improve mitochondrial function in oocytes from aged mice[J].Reproduction,2019,157:345-358.

[52] Altm?e S,Mendoza-Tesarik R,Mendoza C,et al.Effect of growth hormone on uterine receptivity in women with repeated implantation failure in an oocyte donation program:a randomized controlled trial[J].J Endocr Soc,2017,2:96-105.

[53] Cui N,Li AM,Luo ZY,et al.Effects of growth hormone on pregnancy rates of patients with thin endometrium[J].J Endocrinol Invest,2019,42:27-35.

[54] Altm?e S,Aghajanova L.Growth hormone and endometrial receptivity[J].Front Endocrinol (Lausanne),2019,10:653.

[55] Chen Y,Liu F,Nong Y,et al.Clinical efficacy and mechanism of growth hormone action in patients experiencing repeat implantation failure[J].Can J Physiol Pharmacol,2018,96:929-932.

[56] Wang XM,Jiang H,Zhang WX,et al.The effects of growth hormone on clinical outcomes after frozen-thawed embryo transfer[J].Int J Gynecol Obstet,2016,133:347-350.

[57] Bassiouny YA,Dakhly DMR,Bayoumi YA,et al.Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders?A randomized,controlled trial[J].Fertil Steril,2016,105:697-702.

[58] Yang P,Wu R,Zhang H.The effect of growth hormone supplementation in poor ovarian responders undergoing IVF or ICSI:a meta-analysis of randomized controlled trials[J].Reprod Biol Endocrinol,2020,18:76.

[59] Cai MH,Gao LZ,Liang XY,et al.The effect of growth hormone on the clinical outcomes of poor ovarian reserve patients undergoing in vitro fertilization/intracytoplasmic sperm injection treatment:a retrospective study based on POSEIDON criteria[J].Front Endocrinol (Lausanne),2019,10:775.

[60] Chen Y,Tao L,Lin Y,et al.Outcomes of in vitro fertilization-embryo transfer in women with diminished ovarian reserve after growth hormone pretreatment[J].Gynecol Endocrinol,2020,36:955-958.

[61] Gong Y,Zhang K,Xiong D,et al.Growth hormone alleviates oxidative stress and improves the IVF outcomes of poor ovarian responders:a randomized controlled trial[J].Reprod Biol Endocrinol,2020,18:91.

[62] Schwarze JE,Canales J,Crosby J,et al.DHEA use to improve likelihood of IVF/ICSI success in patients with diminished ovarian reserve:a systematic review and meta-analysis[J].JBRA Assist Reprod,2018,22:369-374.

[63] Chern CU,Tsui KH,Vitale SG,et al.Dehydroepiandrosterone(DHEA) supplementation improves in vitro fertilization outcomes of poor ovarian responders,especially in women with low serum concentration of DHEA-S:a retrospective cohort study[J].Reprod Biol Endocrinol,2018,16:90.

[64] Al-Turki HA.Dehydroepiandrosterone supplementation in women undergoing assisted reproductive technology with poor ovarian response.A prospective case-control study[J].J Int Med Res,2018,46:143-149.

[65] Wang Z,Yang AJ,Bao HC,et al.Effect of dehydroepiandrosterone administration before IVF on the live birth rate in poor ovarian responders according to the Bologna criteria:a randomized controlled trial[J].BJOG,2021,doi:10.1111/1471-0528.17045.

[66] Kara M,Aydin T,Aran T,et al.Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve?[J].Eur J Obstet Gynecol Reprod Biol,2014,173:63-65.

[67] Yeung TWY,Chai J,Li RHW,et al.A randomized,controlled,pilot trial on the effect of dehydroepiandrosterone on ovarian response markers,ovarian response,and in vitro fertilization outcomes in poor responders[J].Fertil Steril,2014,102:108-115.

[68] Tanaka T,Huang X,Halicka HD,et al.Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents[J].Cytometry A,2007,71:648-661.

[69] Akarsu S,Gode F,Isik AZ,et al.The association between coenzyme Q10 concentrations in follicular fluid with embryo morphokinetics and pregnancy rate in assisted reproductive techniques[J].J Aassist Reprod Genet,2017,34:599-605.

[70] Turi A,Giannubilo SR,Brugè F,et al.Coenzyme Q10 content in follicular fluid and its relationship with oocyte fertilization and embryo grading[J].Arch Gynecol Obstet,2012,285:1173-1176.

[71] Bentov Y,Hannam T,Jurisicova A,et al.Coenzyme Q10 supplementation and oocyte aneuploidy in women undergoing IVF-ICSI treatment[J].Clin Med insights Reprod Health,2014,8:31-36.

[72] Xu Y,Nisenblat V,Lu C,et al.Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve:a randomized controlled trial[J].Reprod Biol Endocrinol,2018,16:29.

[73] 安东，刘丽敏.补肾类中成药治疗卵巢储备功能下降的Meta分析[J].中国老年学杂志，2021,41:4425-4431.

[74] Liu L,Liu Y,Yang M,et al.Effectiveness of tonifying-kidney and regulating-liver therapy on diminished ovarian reserve:a systematic review and Meta-analysis of randomized controlled trials[J].J Tradit Chin Med,2020,40:343-354.

[75] 罗倩倩，夏桂成，谈勇.高龄妇女生育力减退之备孕策略[J].中华中医药杂志，2021,36:5926-5929.

[76] 邓伟民，赵彦鹏，葛明晓，等.益气血补肝肾中药对体外受精-胚胎移植临床结局的影响[J].辽宁中医药大学学报，2011,13:5-7.

[77] Liu Y,Wu JZ.Effect of Gutai Decoction on the abortion rate of in vitro fertilization and embryo transfer[J].Chin J Integr Med,2006,12:189-193.

[78] Jang S,Kim KH,Jun JH,et al.Acupuncture for in vitro fertilization in women with poor ovarian response:a systematic review[J].Integr Med Res,2020,9:100395.

[79] Davar R,Rahsepar M,Rahmani E.A comparative study of luteal estradiol pre-treatment in GnRH antagonist protocols and in micro dose flare protocols for poor-responding patients[J].Arch Gynecol Obstet,2013,287:149-153.

[80] Fàbregues F,Ferreri J,Méndez M,et al.In vitro follicular activation and stem cell therapy as a novel treatment strategies in diminished ovarian reserve and primary ovarian insufficiency[J].Front Endocrinol(Lausanne),2020,11:617704.

[81] Kawamura K,Ishizuka B,Hsueh AJ.Drug-free in-vitro activation of follicles for infertility treatment in poor ovarian response patients with decreased ovarian reserve[J/OL].Reprod Biomed Online,2020,40:245-253.

[82] Lunding SA,Pors SE,Kristensen SG,et al.Biopsying,fragmentation and autotransplantation of fresh ovarian cortical tissue in infertile women with diminished ovarian reserve[J].Hum Reprod,2019,34:1924-1936.

[83] Herraiz S,Romeu M,Buigues A,et al.Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders[J].Fertil Steril,2018,110:496-505.

[84] Urman B,Boza A,Balaban B.Platelet-rich plasma another add-on treatment getting out of hand?How can clinicians preserve the best interest of their patients?[J].Hum Reprod,2019,34:2099-2103.